News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
552,018 Results
Type
Article (46629)
Company Profile (119)
Press Release (505259)
Multimedia
Podcasts (145)
Webinars (19)
Section
Business (145746)
Career Advice (2421)
Deals (28120)
Drug Delivery (142)
Drug Development (68513)
Employer Resources (158)
FDA (15984)
Job Trends (12065)
News (265566)
Policy (29912)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2320)
Academic (1)
Accelerated approval (37)
Adcomms (36)
Allergies (139)
Alliances (36148)
ALS (164)
Alzheimer's disease (1718)
Antibody-drug conjugate (ADC) (319)
Approvals (16128)
Artificial intelligence (507)
Autoimmune disease (166)
Automation (36)
Bankruptcy (312)
Best Places to Work (9193)
BIOSECURE Act (23)
Biosimilars (194)
Biotechnology (69)
Bladder cancer (160)
Brain cancer (55)
Breast cancer (594)
Cancer (4593)
Cardiovascular disease (418)
Career advice (2048)
Career pathing (39)
CAR-T (261)
CDC (64)
Celiac Disease (1)
Cell therapy (729)
Cervical cancer (35)
Clinical research (58893)
Collaboration (1504)
Company closure (4)
Compensation (1172)
Complete response letters (77)
COVID-19 (2722)
CRISPR (92)
C-suite (807)
Cystic fibrosis (141)
Data (5868)
Decentralized trials (2)
Denatured (33)
Depression (150)
Diabetes (484)
Diagnostics (5561)
Digital health (38)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (224)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (240)
Earnings (62398)
Editorial (68)
Employer branding (20)
Employer resources (142)
Events (82014)
Executive appointments (902)
FDA (19091)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (20)
Funding (1286)
Gene editing (198)
Generative AI (44)
Gene therapy (611)
GLP-1 (1070)
Government (4208)
Grass and pollen (8)
Guidances (377)
Healthcare (14891)
HIV (63)
Huntington's disease (50)
IgA nephropathy (87)
Immunology and inflammation (293)
Immuno-oncology (63)
Indications (108)
Infectious disease (2993)
Inflammatory bowel disease (188)
Inflation Reduction Act (14)
Influenza (112)
Intellectual property (242)
Interviews (454)
IPO (14136)
IRA (58)
Job creations (3174)
Job search strategy (1672)
JPM (67)
Kidney cancer (17)
Labor market (84)
Layoffs (619)
Leadership (41)
Legal (7017)
Liver cancer (90)
Longevity (13)
Lung cancer (610)
Lymphoma (360)
Machine learning (40)
Management (52)
Manufacturing (749)
MASH (169)
Medical device (11590)
Medtech (11637)
Mergers & acquisitions (14985)
Metabolic disorders (1326)
Multiple sclerosis (148)
NASH (22)
Neurodegenerative disease (329)
Neuropsychiatric disorders (100)
Neuroscience (2940)
Neurotech (1)
NextGen: Class of 2026 (4996)
Non-profit (3195)
Now hiring (31)
Obesity (666)
Opinion (283)
Ovarian cancer (154)
Pain (190)
Pancreatic cancer (223)
Parkinson's disease (279)
Partnered (26)
Patents (488)
Patient recruitment (469)
Peanut (55)
People (44250)
Pharmaceutical (33)
Pharmacy benefit managers (32)
Phase 1 (17672)
Phase 2 (25480)
Phase 3 (20878)
Pipeline (5170)
Policy (340)
Postmarket research (2208)
Preclinical (7148)
Press Release (28)
Prostate cancer (242)
Psychedelics (57)
Radiopharmaceuticals (249)
Rare diseases (899)
Real estate (4302)
Recruiting (65)
Regulatory (23255)
Reports (41)
Research institute (2120)
Resumes & cover letters (404)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (153)
Series A (218)
Series B (177)
Service/supplier (8)
Sickle cell disease (97)
Special edition (26)
Spinal muscular atrophy (139)
Sponsored (47)
Startups (2788)
State (1)
Stomach cancer (21)
Supply chain (105)
Tariffs (101)
The Weekly (111)
Vaccines (1110)
Venture capital (97)
Weight loss (467)
Women's health (76)
Worklife (22)
Date
Today (40)
Last 7 days (547)
Last 30 days (2176)
Last 365 days (28129)
2026 (3757)
2025 (28396)
2024 (31398)
2023 (34984)
2022 (45061)
2021 (48499)
2020 (45512)
2019 (36215)
2018 (27397)
2017 (27812)
2016 (25804)
2015 (27975)
2014 (21777)
2013 (17793)
2012 (18968)
2011 (19381)
2010 (17506)
Location
Africa (686)
Alabama (67)
Alaska (6)
Arizona (233)
Arkansas (10)
Asia (32376)
Australia (5673)
California (10536)
Canada (2540)
China (921)
Colorado (410)
Connecticut (466)
Delaware (309)
Europe (79099)
Florida (1600)
Georgia (322)
Hawaii (4)
Idaho (39)
Illinois (753)
India (57)
Indiana (430)
Iowa (22)
Japan (413)
Kansas (106)
Kentucky (27)
Louisiana (19)
Maine (73)
Maryland (1301)
Massachusetts (7621)
Michigan (268)
Minnesota (557)
Mississippi (5)
Missouri (118)
Montana (12)
Nebraska (22)
Nevada (111)
New Hampshire (61)
New Jersey (2829)
New Mexico (15)
New York (2728)
North Carolina (1363)
North Dakota (7)
Northern California (5242)
Ohio (282)
Oklahoma (15)
Oregon (34)
Pennsylvania (2024)
Puerto Rico (18)
Rhode Island (32)
South America (1046)
South Carolina (65)
South Dakota (1)
Southern California (4098)
Tennessee (152)
Texas (1565)
United States (36834)
Utah (268)
Virginia (246)
Washington D.C. (73)
Washington State (835)
West Virginia (4)
Wisconsin (113)
Wyoming (1)
552,018 Results for "almirall prodesfarma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Almirall’s 2025 9M Results
November 10, 2025
·
7 min read
Press Releases
Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne
January 29, 2026
·
8 min read
Press Releases
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
January 16, 2026
·
7 min read
Press Releases
Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference
January 14, 2026
·
8 min read
Press Releases
Almirall H1 2025 Results
July 25, 2025
·
6 min read
FDA
FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm2
Almirall, a global pharmaceutical company dedicated to medical dermatology, announced that the U.S. Food and Drug Administration has approved Almirall’s recent supplemental New Drug Application to expand the use area for its drug, Klisyri, to up to 100 cm2.
June 10, 2024
·
6 min read
Press Releases
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology
September 17, 2025
·
16 min read
Press Releases
Almirall Q1 2025 Results
May 12, 2025
·
8 min read
Business
Almirall’s Nine-month 2023 Results:
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
November 9, 2023
·
19 min read
Press Releases
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025
September 18, 2025
·
7 min read
1 of 55,202
Next
